SmartPeptide
Start Free
CognitiveLimited human evidence

Cerebrolysin

Mixture of low-molecular-weight peptides and free amino acids derived from porcine brain tissue (NOT a single defined peptide — a complex bioactive mixture). Approved in many European, Asian, and Latin American countries for stroke recovery, traumatic brain injury, and Alzheimer's disease. NOT FDA-approved in the US.

Educational only — not medical advice. SmartPeptide does not prescribe, diagnose, or treat. Always consult a licensed healthcare provider before using any peptide, supplement, medication, or protocol.

What the research shows

Multiple RCTs in stroke and TBI populations show modest functional improvements; Cochrane reviews have been mixed (some positive, some inconclusive). Approved use in Europe / Asia / Latin America. Alzheimer's data shows small symptom benefits at best.

What's still experimental

Use outside approved indications. Optimal dosing protocols, treatment duration, and combination with standard rehabilitation are still being refined. US clinical access is essentially zero.

Anecdotal / community reports

Nootropic communities import Cerebrolysin for general cognitive enhancement. These uses are not supported by RCT data in healthy adults and add the risk of unverified product quality.

Anecdotal reports are NOT scientific evidence. They reflect personal experience and may not generalize.

FDA approval status

Source: openFDA + DailyMed (NIH/NLM)
No FDA-approved drug label exists for “Cerebrolysin”. This peptide is not currently approved by the FDA as a finished pharmaceutical product. Any commercial product claiming FDA approval should be treated with suspicion.

Doses studied in research

No established dose range

What published trials tested or FDA-approved labels specify. Reporting research facts — not a SmartPeptide recommendation.

No FDA-approved or established trial dose range for this peptide. Anecdotal ranges discussed in community forums exist but are not supported by published clinical trials, and SmartPeptide will not publish unverified doses.

This is the honest answer for peptides like BPC-157, IGF-1 LR3, MOTS-c, Epitalon and similar research compounds — robust human dose- ranging studies have not been published. Always work with a licensed clinician familiar with experimental peptides if you are considering any use.

How clinicians typically protocol this

Third-party reference · not our recommendation

Dosing phases, cycle lengths, and administration timing as listed in a compounding-pharmacy clinician reference guide. Shown so you can see what a real protocol looks like — and bring informed questions to a licensed clinician.

Third-party protocol referenceCompounding-pharmacy clinician protocol reference (Nov 2025)

Dose numbers, frequencies, and cycle lengths in this panel are extracted from a clinician-facing reference protocol distributed by a US-based compounding pharmacy in November 2025. SmartPeptide has paraphrased all descriptive text and adds no endorsement. Always consult a licensed clinician.

Additional caution for Cerebrolysin

Cerebrolysin is prescription-only in most jurisdictions and administered under clinician supervision. Not self-administered.

Nootropic

Enzymatic hydrolysate of porcine brain protein; a marketed neurotrophic mixture (not a single peptide).

Protocol phases

Low
5 mL/daydaily
intramuscular

mild cognitive support

Moderate
10–20 mL/daydaily
intramuscular or IV

stroke recovery, neurodegenerative disease

High
30–50 mL/daydaily
IV infusion

severe brain injury, advanced neurorehab

Cycle length

Stroke: 10–21 days. Traumatic brain injury: 7–30 days. Vascular dementia / Alzheimer's: 5 days/week × 4 weeks × 2–4 cycles/year.

Protocol notes: Must be administered immediately after opening the ampoule. Do not mix with amino-acid solutions, vitamins, or cardiovascular medications. Flush IV lines with saline before/after. Store at ≤25°C — do not freeze.

Reconstitution calculator Storage & reconstitution guide
Not medical advice. SmartPeptide does not prescribe, diagnose, or treat. The protocol above reproduces dose figures from a third-party clinician reference so you can see what compounding-pharmacy guidance typically looks like — it is not a recommendation for you, and it has not been validated against peer-reviewed dose-ranging trials. Many of these compounds are not FDA-approved for human use. Work with a licensed clinician familiar with peptide therapy before considering anything here.

FDA enforcement & recalls

Live · openFDA Drug Enforcement API
Total actions
2
recalls + withdrawals
Ongoing
2
not yet completed
Class I (serious)
0
health hazard / death risk
  • Class IIOngoing· Voluntary: Firm initiated
    FDA record

    Cerebrolysin for Injection, all strengths and presentations, GenoGenix, LLC, 2840 NW 2nd Ave Ste 204 Boca Raton, FL 33431-6692.

    Reason: Lack of Assurance of Sterility

    Jul 30, 2025·GenoGenix LLC
  • Class IIOngoing· Voluntary: Firm initiated
    FDA record

    CEREBROLYSIN, 107.5 MG/ML, 10 ML vial, The Guyer Institute of Molecular Medicine, Indianapolis, IN

    Reason: Lack of Assurance of Sterility: due to concerns with production processes which cannot assure sterility of products intended to be sterile.

    Nov 30, 2020·Advanced Nutriceuticals, LLC
FDA classifications: Class I = reasonable probability of serious adverse health consequences or death. Class II = temporary or medically reversible adverse consequences. Class III = unlikely to cause adverse health consequences.

Mechanism & targets

ChEMBL · UniProt · Open Targets
No mechanism data indexed in ChEMBL, UniProt, or Open Targets for “Cerebrolysin”. This is common for unscheduled research peptides that haven't been studied in structured target-binding assays.

Live research

PubMed · ClinicalTrials.gov · Europe PMC · OpenAlex
PubMed papers
673
total
Human studies
0
MeSH: humans
Clinical trials
0
published
Active trials
4
42 total registered

Europe PMC — 1,184 additional records

Includes EU/UK studies and PubMed Central full-text articles. Often surfaces research weeks before PubMed indexes it.

Human clinical evidence

Semantic Scholar · AI TLDRs · influence-ranked
Semantic Scholar API is currently rate-limited.

Human-study summaries for “cerebrolysin” are available on Semantic Scholar but the shared free-tier API quota is exhausted right now. Try refreshing in a few minutes, or check the PubMed and Europe PMC panels above for the same literature.

Research funding & verification

NIH RePORTER · CrossRef DOI registry

NIH-funded research

U.S. National Institutes of Health
Funded projects
3
all years
Top award sum
$503K
aggregate USD
Years covered
11
research span
Largest active / recent grants

Publication landscape

CrossRef · DOI registry
Indexed works (CrossRef)
578
all DOIs registered
Retracted papers
0
no retractions on record
Top funders of indexed research
  • University Grants Commission12 works
  • Medicinska Forskningsrådet12 works
  • European Office of Aerospace Research and Development12 works
  • AstraZeneca12 works
  • Air Force Office of Scientific Research12 works
  • Air Force Materiel Command12 works

Funder diversity is a credibility signal. Research concentrated in a single drug company's funding warrants more scrutiny than research funded across NIH, charities, and academic grants.

Preprints — cutting edge

bioRxiv · medRxiv · via Europe PMC

Preprints have NOT been peer-reviewed. They are early research shared by authors before formal validation. Treat findings as preliminary.

Showing 6 of 13 preprints indexed by Europe PMC.

Known risks

Generally well-tolerated in approved use. Hypersensitivity reactions possible (porcine source). Theoretical prion-transmission concerns historically discussed but no documented cases. Quality / sourcing of grey-market product is a serious concern.

Reported side effects

Injection-site reactions, occasional flushing, headache, nausea. Acute hypersensitivity rare but documented.

FDA adverse event reports (FAERS)

Updated quarterly by FDA
Reports filed
81
FAERS, all years
Serious reports
76
94% of reports
Top reporting countries
  • EG22
  • RO10
  • PL7
  • AT5

Most-reported reactions

  • Drug Ineffective
    12
  • Cognitive Disorder
    8
  • Tremor
    8
  • Depression
    7
  • Pain In Extremity
    7
  • Pyrexia
    7
  • Diarrhoea
    6
  • Dyspnoea
    6
  • Multiple Sclerosis Relapse
    6
  • Parkinsonism
    6

Counts from FDA Adverse Event Reporting System (FAERS). Voluntary reports — they show what was reported, not whether the drug caused the event. Many reports lack confirmation. FAERS docs

What requires medical supervision

Approved indications require prescriber-supervised administration. Outside approved indications, work with a clinician familiar with the literature.

Questions for your clinician

  • Do I have an indication (post-stroke, TBI, vascular dementia) where Cerebrolysin has demonstrated benefit?
  • What does our local rehabilitation protocol look like vs. adding Cerebrolysin?
  • What's the sourcing concern with imported product?

Editorially curated references

Discussions about Cerebrolysin

Start a discussion
No discussions yet — be the first. Share what you've learned, what worked, what didn't, or a study you want translated into plain English.
See all Cerebrolysin discussions Native, moderated, no buying or selling